Thiol Proteases: Inhibitors and Potential Therapeutic Targets

Authors: Leung-Toung, Regis1; Zhao, Yanqing1; Li, Wanren1; Tam, Tim F.1; Karimian, Khashayar1; Spino, Michael1

Source: Current Medicinal Chemistry, Volume 13, Number 5, March 2006 , pp. 547-581(35)

Publisher: Bentham Science Publishers

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

A better understanding of the biological roles and the pathological consequences of thiol-dependent enzymes has emerged in recent years, and hence considerable progress has been made in identifying and delineating cysteine proteases that can be considered promising drug targets from those involved in housekeeping functions. Cysteine proteases have been implicated in a wide variety of disease processes ranging from cardiovascular, inflammatory, viral and immunological disorders to cancer.

The first milestone in drug development of cysteine protease inhibitors has probably been reached, as IDN-6556 (a broad spectrum caspase inhibitor) has recently received Orphan Drug label by the U.S. Food and Drug Administration for use in the treatment of the patients undergoing liver transplantation and other solid organ transplantation. IDN-6556, which blocks apoptosis, is in Phase II human clinical trial in patients undergoing liver transplantation. In addition, more than ten cysteine protease inhibitors are presently at various phases of clinical development/trials for diverse diseases.

This review emphasises on the new development from the literature reports since the year 2000 in the exploration of potential cysteine proteases as prospective drug targets, and the investigation of promising inhibitors that can potentially be developed for the treatment of human diseases. Transglutaminases, another class of thiol-dependent enzymes, are not discussed here.

Keywords: Cysteine proteases; cathepsins; calpain; caspase; rhinovirus-3C and SARS-CoV 3CLpro

Document Type: Research article

DOI: 10.2174/092986706776055733

Affiliations: 1: Medicinal Chemistry Department, Apotex Research, Inc., 400 Ormont Drive, Toronto, Ontario M9L 1N9, Canada.

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A